Krystal Biotech, Inc.
General ticker "KRYS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.6B (TTM average)
Krystal Biotech, Inc. follows the US Stock Market performance with the rate: 57.7%.
Estimated limits based on current volatility of 2.4%: low 292.80$, high 307.19$
Factors to consider:
- Total employees count: 275 as of 2024
- Top business risk factors: Dependence on VYJUVEK, Geopolitical risks, Strategic risks and growth management, Social media risks, Intellectual property risks
- Current price 14.4% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [173.69$, 263.82$]
- 2026-12-31 to 2027-12-31 estimated range: [172.70$, 264.36$]
Financial Metrics affecting the KRYS estimates:
- Negative: with PPE of 36.0 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 41.45 > 18.39
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.31 > 6.06
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Shareholder equity ratio, % of 91.44 > 64.29
- Positive: -0.02 < Operating cash flow per share per price, % of 2.82
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term KRYS quotes
Long-term KRYS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $50.70MM | $290.51MM | $389.13MM |
| Operating Expenses | $160.43MM | $224.82MM | $227.84MM |
| Operating Income | $-109.73MM | $65.69MM | $161.29MM |
| Non-Operating Income | $122.62MM | $29.66MM | $28.18MM |
| R&D Expense | $46.43MM | $53.58MM | $58.05MM |
| Income(Loss) | $12.90MM | $95.36MM | $189.47MM |
| Taxes | $1.97MM | $6.20MM | $-15.36MM |
| Net Income(Loss)* | $10.93MM | $89.16MM | $204.83MM |
| Stockholders Equity | $778.64MM | $946.38MM | $1,219.56MM |
| Inventory | $6.99MM | $26.51MM | $40.48MM |
| Assets | $818.36MM | $1,055.84MM | $1,333.79MM |
| Operating Cash Flow | $-88.80MM | $123.42MM | $200.87MM |
| Capital expenditure | $11.80MM | $4.24MM | $11.95MM |
| Investing Cash Flow | $82.64MM | $-163.44MM | $-58.42MM |
| Financing Cash Flow | $202.75MM | $27.01MM | $8.71MM |
| Earnings Per Share** | $0.40 | $3.12 | $7.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.